Ivabradine did not reduce the occurrence of myocardial injury after noncardiac surgery (MINS), according to late-breaking research presented in a Hot Line session today at ESC Congress 2025. MINS is a ...

Please provide your email address to receive an email when new articles are posted on . Initiating ivabradine before discharge among patients with stabilized HF increased ivabradine use at 180 days ...

Patients with postural orthostatic tachycardia syndrome treated with ivabradine have better heart-rate control when standing. HealthDay News — Ivabradine lowers heart rate (HR) and relieves symptoms ...

SILVER SPRING, MD — Response to the recent approval of the heart-rate–slowing drug ivabradine (Corlanor, Amgen) by the US Food and Drug Administration (FDA) has included cautious enthusiasm as well as ...

The heart failure drug ivabradine (Corlanor) can provide relief from the elevated heart rate and often debilitating symptoms associated with postural orthostatic tachycardia syndrome (POTS), a new ...

The heart-rate-lowering drug ivabradine significantly reduces the risk of cardiovascular death and hospitalisation for worsening heart failure when added to standard treatment in patients with heart ...

Here, we report the case of a 54-year-old man with an inoperable metastatic paraganglioma in whom systemic targeted radiotherapy with 177 Lu-Dotatate was indicated. He had hypertension and tachycardia ...

The ASSOCIATE study investigators have reported that the I f current inhibitor, ivabradine, is safe, improves exercise performance, and delays the development of ischemia in patients with chronic ...

Use of the heart-rate lowering drug ivabradine can reduce the incidence of cardiovascular disease and death in patients with coronary artery disease and a high heart rate. These are the conclusions of ...

THOUSAND OAKS, Calif., Aug. 27, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the U.S. Food and Drug Administration (FDA) has granted priority review designation for ivabradine for the ...

THOUSAND OAKS, Calif., April 15, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of Corlanor ® (ivabradine), an oral ...